Evolocumab cut combined heart and stroke risk in kidney impairment
Evolocumab reduced the relative risk of coronary heart disease death, heart attack or stroke by 39% versus placebo in people with reduced kidney function.Evolocumab reduced the relative risk of coronary heart disease death, heart attack or stroke by 39% versus placebo in people with reduced kidney function.